BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV, Tan H, Madsen A, Valdez H, Cohen SB. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open 2021;7:e001595. [PMID: 34045358 DOI: 10.1136/rmdopen-2021-001595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 2022:annrheumdis-2022-222608. [PMID: 35788492 DOI: 10.1136/ard-2022-222608] [Reference Citation Analysis]
2 Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 2021:annrheumdis-2021-221276. [PMID: 34706874 DOI: 10.1136/annrheumdis-2021-221276] [Reference Citation Analysis]
3 Kim JW, Kim SY. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment. Int J Mol Sci 2021;22:11322. [PMID: 34768752 DOI: 10.3390/ijms222111322] [Reference Citation Analysis]
4 Wells GA, Tugwell P, Tomasson G, Guillemin F, Maxwell LJ, Shea BJ, Grosskleg S, Merkel PA, March L, Beaton DE. Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. Semin Arthritis Rheum 2021;51:1370-7. [PMID: 34863558 DOI: 10.1016/j.semarthrit.2021.11.001] [Reference Citation Analysis]